# AURELIO-03 (NCT04234113)

> Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

No report yet. It can be ordered.

- Drugs tested: nanrilkefusp alfa (SOT101); nanrilkefusp alfa (SOT101) plus pembrolizumab
- Indication: advanced/metastatic solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04234113
- Phase: PHASE1
- Status: TERMINATED
- Sponsor: SOTIO Biotech AG
- Conditions: Thyroid Cancer; Renal Cell Carcinoma; Non Small Cell Lung Cancer; Small-cell Lung Cancer; Bladder Cancer; Melanoma; Merkel Cell Carcinoma; Skin Squamous Cell Carcinoma; Microsatellite Instability High; Triple Negative Breast Cancer; Mesothelioma; Thymic Cancer; Cervical Cancer; Biliary Tract Cancer; Hepatocellular Carcinoma; Ovarian Cancer; Gastric Cancer; Head and Neck Squamous Cell Carcinoma; Anal Cancer
- Interventions: Nanrilkefusp alfa; Pembrolizumab
- Enrollment: 115
- Primary outcome: Number of Participants With Dose-limiting Toxicities (DLTs)
- Primary outcome: Number of Participants With Adverse Events (AEs)
- Primary outcome: Number of Participants With Serious AEs (SAEs)
- Primary outcome: Number of Participants With AEs Leading to Premature Discontinuation of Nanrilkefusp Alfa
- Primary outcome: Number of Participants Who Died
- Primary outcome: Number of Participants With Nanrilkefusp Alfa-related Clinical Laboratory Test Abnormalities (Coagulation; Hematology; Clinical Chemistry; Urinalysis; Thyroid and Cardiac Function)

## Indexed commentary on AURELIO-03 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=aurelio-03-nct04234113